Results 31 to 40 of about 978,474 (275)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis

open access: yesKidney & Blood Pressure Research, 2018
Background/Aims: Whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) could benefit patients with diabetes and albuminuria remains controversial.
Kanran Wang   +7 more
doaj   +1 more source

Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials.

open access: yesPLoS ONE, 2021
IntroductionThis meta-analysis aimed to summarize the available evidence to compare angiotensin-converting enzyme (ACE) inhibitors with angiotensin II receptor blockers (ARBs) on improving insulin sensitivity in hypertensive patients.MethodsRandomized ...
Jia Yao   +5 more
doaj   +1 more source

Advances in Ace Inhibitors

open access: yes, 2020
<p> Angiotensin-converting-enzyme inhibitors (ACE inhibitors) are a class of medication used primarily for the treatment of high blood pressure and heart failure.
Ruth L. Coleman   +5 more
core   +1 more source

Secondary prevention of coronary heart disease in older patients after the national service framework: population based study [PDF]

open access: yes, 2006
Objective To examine the extent of uptake of medication for secondary prevention of coronary heart disease in older British men and women before (1998-2001) and after (2003) the implementation of the national service framework.Design Two population based,
Morris, RW   +15 more
core   +1 more source

ACE Inhibitors and Chronotherapy

open access: yesClinical and Experimental Hypertension, 2005
Chronotherapy can improve the effectiveness and reduce the adverse reactions of drugs and actually is used for several conditions including cardiovascular diseases. Although angiotensin converting enzyme (ACE) inhibitors are available for the therapy of patients with hypertension and/or heart failure, these agents have some characteristic adverse ...
Masami, Ohmori, Akio, Fujimura
openaire   +2 more sources

Prodrug ACE Inhibitors [PDF]

open access: yesCirculation, 1998
To the Editor: In a recent issue of Circulation , Brown and Vaughan1 reviewed ACE inhibitors. They stated that captopril and lisinopril are active drugs and listed 7 other ACE inhibitors approved in the United States that are inactive prodrugs until metabolized in the liver.
openaire   +2 more sources

Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes [PDF]

open access: yes, 1994
Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Anaphylactoid reactions (AR) are the most feared complications of hemodialysis.
Yves Vanrenterghem   +7 more
core   +1 more source

Social Functioning Within the First Years After Pediatric Brain Tumor Diagnosis and the Relationship With Family Psychosocial Risk

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben   +4 more
wiley   +1 more source

ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm. [PDF]

open access: yesPLoS ONE, 2014
Independent of their blood pressure lowering effect, ACE inhibitors are thought to reduce vascular inflammation. The clinical relevance of this effect is unclear with the current knowledge.
Kim E Kortekaas   +6 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy